<DOC>
	<DOC>NCT00451958</DOC>
	<brief_summary>Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.</brief_summary>
	<brief_title>A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion/ Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated. Signed informed consent The patients must have completed the FE 200486 CS21 Study.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Degarelix</keyword>
	<keyword>prostate cancer</keyword>
</DOC>